{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:41:13Z","timestamp":1772466073149,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"U-EXCEL","award":["NCT03345849"],"award-info":[{"award-number":["NCT03345849"]}]},{"name":"U-EXCEED","award":["NCT03345836"],"award-info":[{"award-number":["NCT03345836"]}]},{"name":"U-ENDURE","award":["NCT03345823"],"award-info":[{"award-number":["NCT03345823"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Importance and Objective<\/jats:title>\n                    <jats:p>Upadacitinib, an oral, reversible Janus kinase inhibitor, is approved for the treatment of moderate-to-severe Crohn\u2019s disease (CD). Limiting corticosteroid exposure is an important goal in treating CD. This posthoc analysis evaluated the corticosteroid-sparing effects of upadacitinib in patients with CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and Setting<\/jats:title>\n                    <jats:p>This study included pooled data from two phase 3, multicenter, double-blind induction trials and one maintenance trial. Randomization was stratified by corticosteroid use at induction baseline, with a mandatory corticosteroid taper starting at induction week 4. Efficacy was evaluated by baseline corticosteroid use and by achieving corticosteroid-free outcomes through year 2 of maintenance therapy. Safety was also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, 34.7% (234\/674) and 35.7% (124\/347) of upadacitinib 45\u2009mg and placebo-treated patients were taking corticosteroids, respectively. At induction week 12 and maintenance week 52, higher rates of upadacitinib-treated patients were corticosteroid-free among all patients and among patients with baseline corticosteroid use compared with placebo; upadacitinib-treated patients achieved higher rates of corticosteroid-free outcomes, compared with placebo, including corticosteroid-free clinical remission (stool frequency\/abdominal pain score [SF\/APS]: 42.7% vs 16.1%; CD activity index [CDAI]: 41.2% vs 23.4%) and corticosteroid-free endoscopic response (37.0% vs 8.1%), with similar results observed among responders to upadacitinib induction therapy at maintenance week 52. Corticosteroid-free outcomes were sustained through year 2 of maintenance therapy. The safety profile was similar to the overall population, with no new safety risks identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The results from pivotal studies demonstrated that upadacitinib effectively induced early and sustainable corticosteroid-free clinical remission with a manageable safety profile in patients with moderate-to-severe CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial identifiers<\/jats:title>\n                    <jats:p>U-EXCEL, U-EXCEED, and U-ENDURE ClinicalTrials.gov numbers, NCT03345849, NCT03345836, and NCT03345823.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf250","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:52:07Z","timestamp":1759492327000},"page":"498-511","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn\u2019s Disease"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4968-5795","authenticated-orcid":false,"given":"Marla C","family":"Dubinsky","sequence":"first","affiliation":[{"name":"Division of Pediatric Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert","family":"D\u2019Haens","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Center , Amsterdam,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Dewit","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Clin. Univ. Saint Luc , UCLouvain, Brussels,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0947-5235","authenticated-orcid":false,"given":"Pascal","family":"Juillerat","sequence":"additional","affiliation":[{"name":"Clinic for Visceral Surgery and Medicine, Bern University Hospital , Bern,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, University of Calgary , Calgary, AB,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimitsu","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Dubcenco","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula","family":"Lacerda","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel I","family":"Anyanwu","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharanya","family":"Ford","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colla","family":"Cunneen","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Fish","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namita","family":"Joshi","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Garrison","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward V","family":"Loftus","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic School of Medicine and Science , Rochester, MN,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2026030209520990000_izaf250-B1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","article-title":"Crohn\u2019s disease","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet"},{"key":"2026030209520990000_izaf250-B2","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med"},{"key":"2026030209520990000_izaf250-B3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/ecco-jcc\/jjv218","article-title":"Self-reported symptom burden in individuals with inflammatory bowel disease","volume":"10","author":"Farrell","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2026030209520990000_izaf250-B4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2020.18936","article-title":"Management of Crohn disease: a review","volume":"325","author":"Cushing","year":"2021","journal-title":"JAMA"},{"key":"2026030209520990000_izaf250-B5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.gastha.2022.07.003","article-title":"Poor patient-reported outcomes and impaired work productivity in patients with inflammatory bowel disease in remission","volume":"1","author":"Cross","year":"2022","journal-title":"Gastro Hep Adv"},{"key":"2026030209520990000_izaf250-B6","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjaa053","article-title":"The historical role and contemporary use of corticosteroids in inflammatory bowel disease","volume":"14","author":"Dorrington","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026030209520990000_izaf250-B7","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/apt.13803","article-title":"Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis","volume":"44","author":"D\u2019Haens","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2026030209520990000_izaf250-B8","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/jgh3.12841","article-title":"Chronic steroid use: an overlooked impact on patients with inflammatory bowel disease","volume":"6","author":"Farraj","year":"2022","journal-title":"JGH Open"},{"key":"2026030209520990000_izaf250-B9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026030209520990000_izaf250-B10","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/apt.15497","article-title":"Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients","volume":"50","author":"Selinger","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026030209520990000_izaf250-B11","volume-title":"Administration FDA.","author":"AbbVie"},{"key":"2026030209520990000_izaf250-B12","volume-title":"Agency EM.","author":"AbbVie"},{"key":"2026030209520990000_izaf250-B13","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"2026030209520990000_izaf250-B14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s41669-023-00419-w","article-title":"Content validity and psychometric evaluation of the functional assessment of chronic illness therapy-fatigue (FACIT-Fatigue) in patients with Crohn\u2019s disease and ulcerative colitis","volume":"7","author":"Loftus","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"2026030209520990000_izaf250-B15","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s10620-019-05959-y","article-title":"Corticosteroid treatment at diagnosis: an analysis of relapses, disease extension, and colectomy rate in ulcerative colitis","volume":"65","author":"Bertani","year":"2020","journal-title":"Dig Dis Sci"},{"key":"2026030209520990000_izaf250-B16","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/apt.14334","article-title":"A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease","volume":"46","author":"Selinger","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026030209520990000_izaf250-B17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CEG.S58152","article-title":"Pharmacologic therapy for inflammatory bowel disease refractory to steroids","volume":"8","author":"Mart\u00ednez-Montiel","year":"2015","journal-title":"Clin Exp Gastroenterol"},{"key":"2026030209520990000_izaf250-B18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/ajg.2017.479","article-title":"Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-\u03b1-directed therapy for inflammatory bowel disease","volume":"113","author":"Lewis","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2026030209520990000_izaf250-B19","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/MIB.0000000000001261","article-title":"Safety considerations with the use of corticosteroids and biologic therapies in mild-to-moderate ulcerative colitis","volume":"23","author":"Cross","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026030209520990000_izaf250-B20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ibd\/izz193","article-title":"Corticosteroid-free remission vs overall remission in clinical trials of moderate-severe ulcerative colitis and Crohn\u2019s disease","volume":"26","author":"George","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026030209520990000_izaf250-B21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2009.09.056","article-title":"Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn\u2019s disease","volume":"138","author":"Baert","year":"2010","journal-title":"Gastroenterology"},{"key":"2026030209520990000_izaf250-B22","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2026030209520990000_izaf250-B23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/ibd\/izae200","article-title":"Induction of endoscopic response, remission, and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes and quality of life in patients with Crohn\u2019s disease","volume":"31","author":"Pan\u00e9s","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026030209520990000_izaf250-B24","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/ecco-jcc\/jjae092","article-title":"Adaptive steroid tapering impedes corticosteroid-free remissions compared with forced tapering in clinical trials of ulcerative colitis","volume":"18","author":"Narula","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026030209520990000_izaf250-B25","doi-asserted-by":"crossref","first-page":"i706","DOI":"10.1093\/ecco-jcc\/jjac190.0708","article-title":"P578 Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trials","volume":"17","author":"Pan\u00e9s","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026030209520990000_izaf250-B26","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.cgh.2024.02.027","article-title":"Upadacitinib reduces Crohn\u2019s disease symptoms within the first week of induction therapy","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026030209520990000_izaf250-B27","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.cgh.2024.02.026","article-title":"Upadacitinib achieves clinical and endoscopic outcomes in Crohn\u2019s disease regardless of prior biologic exposure","volume":"22","author":"Peyrin-Biroulet","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026030209520990000_izaf250-B28","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.3390\/jcm13092652","article-title":"Prevalence of the oral corticosteroid exposure and excessive use in patients with inflammatory bowel disease: data from four French Referral Centers of the International DICE Study","volume":"13","author":"Nancey","year":"2024","journal-title":"J Clin Med"},{"key":"2026030209520990000_izaf250-B29","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.dld.2024.01.180","article-title":"Factors associated with corticosteroid use in Crohn\u2019s disease and ulcerative colitis patients in Israel: a multicenter cross-sectional study","volume":"56","author":"Barkan","year":"2024","journal-title":"Dig Liver Dis"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/3\/498\/65172871\/izaf250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/3\/498\/65172871\/izaf250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:52:23Z","timestamp":1772463143000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/3\/498\/8313916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf250","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,11,4]]}}}